TD 8954

Drug Profile

TD 8954

Alternative Names: TAK 954; TD8954

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Theravance
  • Developer Theravance; Theravance Biopharma
  • Class Antidementias; Benzimidazoles; Carboxylic acids; Piperidines; Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastrointestinal motility disorders
  • Discontinued Alzheimer's disease

Most Recent Events

  • 06 Oct 2017 Takeda plans a phase I trial in Healthy volunteers (NCT03296787)
  • 16 Sep 2017 Takeda plans a phase II trial for Diabetic gastroparesis or Idiopathic gastroparesis (NCT03281577)
  • 14 Sep 2017 Takeda plans a phase I trial in Healthy volunteers (NCT03277274)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top